thermo- and air-stable Pd0 complex from readily available electron-poor trifluoromethylated phosphine was serendipitously discovered. As detailed and comparative DFT calculations indicate, the stability of the complex is associated with unusually strong ligand–ligand noncovalent interactions. The unique stability and the presence of hydrophobic structural elements of the complex offer several practical
Iron-catalyzedacetylation of electron deficient N-heteroarenes has been reported using triethylorthoformate as robust and inexpensive acetyl source. This new method is successfully applied for the acetylation of quinolines, isoquinoline, quinoxalines, arylpyridines, bipyridines, and benzothiazole.
A tetrazolinone compound represented by formula (1):
wherein Q represents a 6-membered aromatic heterocyclic group optionally having one or more atoms or groups selected from Group P
1
, provided that a heteroatom constituting the heterocyclic group is a nitrogen atom, and the number of nitrogen atom is 1, 2, or 3; R
1
, R
2
, R
3
, and R
11
each represents a C1-C6 alkyl group optionally having one or more atoms or groups selected from Group P
2
; R
4
and R
5
each represents a hydrogen atom, etc.; R
6
represents a C1-C6 alkyl group optionally having one or more halogen atoms, etc.; R
7
, R
8
, and R
9
each represents a hydrogen atom, etc.; and X represents an oxygen atom or a sulfur atom, has excellent control activity against pests.
Benzylamine as an arylcarboxy surrogate: a copper catalysed o-benzoxylation of 2-phenylpyridines using benzyl amines
作者:Ahalya Behera、Saroj K. Rout、Srimanta Guin、Bhisma K. Patel
DOI:10.1039/c4ra09922b
日期:——
Different reactivities and selectivities of Cu and Pd catalysts have been demonstrated in the reactions of benzylamines with 2-phenylpyridines.
铜和钯催化剂在苄胺与2-苯基吡啶反应中表现出不同的活性和选择性。
2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders
申请人:Garcia-Echeverria Carlos
公开号:US20080132504A1
公开(公告)日:2008-06-05
Novel pyrimidine derivatives of formula I
to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them